A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial to Evaluate the EBA, Safety and PK of Orally Administered LCB01-0371 in Adult Patients With Smear-positive Pulmonary Tuberculosis
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs LCB01-0371 (Primary) ; Linezolid; Rifampicin/isoniazid/pyrazinamide/ethambutol
- Indications Pulmonary tuberculosis
- Focus Therapeutic Use
- Sponsors LegoChem Biosciences
- 31 Aug 2017 Number of arms has changed from 3 to 5 ,hence patient number has alson changed from 30 to 64.
- 28 Aug 2017 Planned number of patients changed from 30 to 64.
- 28 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.